NCT02217839View on ClinicalTrials.gov

Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2013

Conditions
Healthy
Interventions
DRUG

DG3173

DRUG

DG3173+Octreotide

DRUG

Octreotide

DRUG

DG3173 Placebo

DRUG

DG3173 Placebo+Octreotide Placebo

DRUG

Octreotide+DG3173 Placebo

Sponsors
All Listed Sponsors
lead

Aspireo Pharmaceuticals Limited

INDUSTRY